Any current/future new fundraising through debt or equity?

Chemcon Specialty Chemicals Limited has ongoing capital expenditure projects, specifically plants P8 and P9, funded by IPO proceeds and internal accruals. Rs. 25 Crores of capex has already been incurred, with further expenditure ongoing for these new plants. No explicit mention of any new or future fundraising through additional debt or equity beyond the IPO proceeds used for current expansions. The company is focusing on capacity expansions, new product commercialization, and increasing production volumes funded by internal resources and the IPO. No clear statement on plans for further capit

Any current/future capex/capital investment/strategic investment?

Ongoing capital expenditure on plants P8 and P9, funded partly by IPO proceeds and internal accruals; about Rs. 25 Crores incurred so far. P8 plant expected to be commercialized in approximately 5 to 5.5 months, and P9 plant around 12 months from the call date (Feb 2021). The new multipurpose plants (P8 & P9) will support existing products and enable manufacturing of new products such as 4-chlorobutyryl chloride, 2,5 DHT, and expanded CMIC capacity. Total volumetric reactor capacity after expansion will be ~625 kl. Future capex beyond P8 & P9 not specifically detailed but focus remains on cont

Future growth expectations in sales/revenue/volumes?

Targeted growth of around 15% to 20% in HMDS volumes (Page 11). Around 30% growth expected in CMIC volumes, plus addition of new products (Page 11). Plan to increase production capacities and real-time production by 30% in FY2022 (Page 16). New products like 4-chlorobutyryl chloride and 2,5-DHT expected to contribute Rs. 75-100 Crores revenue each with less than 1-year capex payback period (Pages 12, 5-6). Expansion plants P8 and P9 to commercialize new and existing products, with P8 commercializing in ~5-5.5 months and P9 in ~12 months (Pages 5, 8). Bromide volumes expected to recov

Future growth expectations in earnings/operating earnings/profits/EPS?

Targeted growth of around 15% to 20% in HMDS segment and around 30% in CMIC segment over the next few years. New product additions expected to contribute significantly, with capex payback period less than a year and expected topline of Rs. 75-100 Crores per new product. Capacity expansions (plants P8 and P9) underway, with P8 commercializing in approx. 5-5.5 months and P9 in about 12 months, expected to support growth. Volume growth and new product commercialization are key growth drivers. Margins expected to remain stable with improvements from higher volumes and cost efficiencies. Overall lo

Current/ Expected Orderbook/ Pending Orders?

The bromide business is showing signs of recovery with pending orders and clearances initiating dispatches and supplies. Kamal Aggarwal mentioned that about 60% to 70% of the bromide volume pending will be recovered in the current quarter. The company is getting volume requirements and anticipates business recovery in the bromide segment. New products like 4-chlorobutyryl chloride and 2,5 DHT have started commercial supplies, indicating an expanding order book. Expansion projects (P8 and P9) are underway, expected to enhance production capacity and order fulfillment ability within 5-12 months.

Chemcon Speciality Chemicals LtdQ3 FY21Chemicals & Petrochemicals

Chemcon Speciality Chemicals Ltd Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹216P/E: 29.6Market Cap: ₹835 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Targeted growth of around 15% to 20% in HMDS volumes (Page 11).
Around 30% growth expected in CMIC volumes, plus addition of new products (Page 11).
Plan to increase production capacities and real-time production by 30% in FY2022 (Page 16).
New products like 4-chlorobutyryl chloride and 2,5-DHT expected to contribute Rs. 75-100 Crores revenue each with less than 1-year capex payback period (Pages 12, 5-6).
Expansion plants P8 and P9 to commercialize new and existing products, with P8 commercializing in ~5-5.5 months and P9 in ~12 months (Pages 5, 8).
Bromide volumes expected to recover to 60-70% of earlier quarterly levels (~1 million kg) (Page 16).
Focus on penetrating new clients, new geographic markets, and ongoing cost efficiencies as growth levers (Page 16).
Innovation pipeline includes adding at least 2 new products annually (Page 12).

Margin guidance

Category 3

Targeted growth of around 15% to 20% in HMDS segment and around 30% in CMIC segment over the next few years.
New product additions expected to contribute significantly, with capex payback period less than a year and expected topline of Rs. 75-100 Crores per new product.
Capacity expansions (plants P8 and P9) underway, with P8 commercializing in approx. 5-5.5 months and P9 in about 12 months, expected to support growth.
Volume growth and new product commercialization are key growth drivers.
Margins expected to remain stable with improvements from higher volumes and cost efficiencies.
Overall long-term vision to multiply current market value several times with leadership in products and continuous innovation.
Working to reduce client concentration through exports, aiming to expand geographic reach and market share.
Expect overall business growth supported by increasing demand in pharma chemicals and oil well completion sectors.

See what Chemcon Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Chemcon Specialty Chemicals Limited has ongoing capital expenditure projects, specifically plants P8 and P9, funded by IPO proceeds and internal accruals.
Rs. 25 Crores of capex has already been incurred, with further expenditure ongoing for these new plants.
No explicit mention of any new or future fundraising through additional debt or equity beyond the IPO proceeds used for current expansions.
The company is focusing on capacity expansions, new product commercialization, and increasing production volumes funded by internal resources and the IPO.
No clear statement on plans for further capital raising was provided in the call.

Order book

The bromide business is showing signs of recovery with pending orders and clearances initiating dispatches and supplies.
Kamal Aggarwal mentioned that about 60% to 70% of the bromide volume pending will be recovered in the current quarter.
The company is getting volume requirements and anticipates business recovery in the bromide segment.
New products like 4-chlorobutyryl chloride and 2,5 DHT have started commercial supplies, indicating an expanding order book.
Expansion projects (P8 and P9) are underway, expected to enhance production capacity and order fulfillment ability within 5-12 months.
The working capital on receivables is Rs. 85 Crores as of nine months FY2021, reflecting business carried out and orders in process.

See what Chemcon Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing capital expenditure on plants P8 and P9, funded partly by IPO proceeds and internal accruals; about Rs. 25 Crores incurred so far.
P8 plant expected to be commercialized in approximately 5 to 5.5 months, and P9 plant around 12 months from the call date (Feb 2021).
The new multipurpose plants (P8 & P9) will support existing products and enable manufacturing of new products such as 4-chlorobutyryl chloride, 2,5 DHT, and expanded CMIC capacity.
Total volumetric reactor capacity after expansion will be ~625 kl.
Future capex beyond P8 & P9 not specifically detailed but focus remains on continuous product additions and capacity expansions.
New product additions target revenue sizes of Rs. 75-100 Crores with a payback period of under one year.
Strategic emphasis on penetrating new clients, new geographic markets, and ongoing cost efficiencies to drive growth.

Track Chemcon Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does Chemcon Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisChemcon Speciality Chemicals Ltd

Rev 3Mar 3

See where Chemcon Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Chemcon Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Chemcon Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q3 FY21) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Chemcon Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Chemcon Speciality Chemicals Ltd Q3 FY21 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Chemcon Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Chemcon Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season